Fabrication of mesoporous silica nanoparticles for targeted delivery of sunitinib to ovarian cancer cells.
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 255, doi. 10.34172/bi.2023.25298
- By:
- Publication type:
- Article
Works matching IS 22285652 AND DT 2023 AND VI 13 AND IP 3
Results: 8
1
2
PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy.
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 241, doi. 10.34172/bi.2023.24252
- By:
- Publication type:
- Article
3
Differentiation of human endometrial stem cells encapsulated in alginate hydrogel into oocyte-like cells.
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 229, doi. 10.34172/bi.2022.23960
- By:
- Publication type:
- Article
4
Artesunate reduces sepsis-mediated acute lung injury in a SIRT1-dependent manner.
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 219, doi. 10.34172/bi.2023.23585
- By:
- Publication type:
- Article
5
Synthesis, characterization, and evaluation of pH-sensitive doxorubicin-loaded functionalized graphene oxide in osteosarcoma cells.
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 207, doi. 10.34172/bi.2022.23820
- By:
- Publication type:
- Article
6
Apoptotic effects of human amniotic fluid mesenchymal stem cells conditioned medium on human MCF-7 breast cancer cell line.
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 191, doi. 10.34172/bi.2022.23813
- By:
- Publication type:
- Article
7
Homozygous mutation in CSF1R causes brain abnormalities, neurodegeneration, and dysosteosclerosis (BANDDOS).
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 183, doi. 10.34172/bi.2022.23528
- By:
- Publication type:
- Article
8
The implications of pharmacogenomics in oncology.
- Published in:
- BioImpacts, 2023, v. 13, n. 3, p. 181, doi. 10.34172/bi.2023.27686
- By:
- Publication type:
- Article